US 12,187,788 B2
Methods for treating atopic dermatitis and related disorders
Gene Colice, Gaithersburg, MD (US); Rene van der Merwe, Thriplow (GB); and Paul Baverel, Cambridge (GB)
Assigned to MedImmune Limited, Cambridge (GB)
Filed by MedImmune Limited, Cambridge (GB)
Filed on Oct. 30, 2020, as Appl. No. 17/084,957.
Claims priority of provisional application 63/068,593, filed on Aug. 21, 2020.
Claims priority of provisional application 63/061,497, filed on Aug. 5, 2020.
Claims priority of provisional application 63/037,783, filed on Jun. 11, 2020.
Claims priority of provisional application 62/993,443, filed on Mar. 23, 2020.
Prior Publication US 2021/0301010 A1, Sep. 30, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/24 (2006.01); A61K 9/00 (2006.01); A61K 39/395 (2006.01); A61P 17/04 (2006.01); A61K 31/573 (2006.01); A61K 45/06 (2006.01); A61P 25/20 (2006.01); A61P 25/22 (2006.01); A61P 25/24 (2006.01); A61P 31/04 (2006.01)
CPC C07K 16/244 (2013.01) [A61K 9/0019 (2013.01); A61K 39/3955 (2013.01); A61P 17/04 (2018.01); A61K 31/573 (2013.01); A61K 45/06 (2013.01); A61P 25/20 (2018.01); A61P 25/22 (2018.01); A61P 25/24 (2018.01); A61P 31/04 (2018.01); C07K 2317/51 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/624 (2013.01)] 37 Claims
 
1. A method of treating atopic dermatitis (AD) in a subject in need thereof, wherein the method comprises the steps of: (a) administering a first dose of about 300 mg of an IL-13 binding protein to the subject; and (b) administering one or more secondary dose(s) of about 300 mg of the IL-13 binding protein to the subject, wherein each secondary dose is administered to the subject about 4 weeks after the immediately preceding dose, wherein prior to step (a) the method further comprises a step of administering a first prior dose of the IL-13 binding protein followed by one or more prior dose(s) of the IL-13 binding protein to the subject, such that each of the one or more prior dose(s) of the IL-13 binding protein is administered to the subject about 2 weeks after the immediately preceding prior dose, and wherein the IL-13 binding protein is an anti-IL-13 antibody, or an IL-13 binding fragment thereof, comprising a heavy chain variable region (HCVR) and a light chain variable region (LCVR), wherein:
(i) the heavy chain variable region comprises:
a heavy chain complementarity determining region 1 (HCDR1) comprising the amino acid sequence of SEQ ID NO:1; a heavy chain complementarity determining region 2 (HCDR2) comprising the amino acid sequence of SEQ ID NO: 2; and a heavy chain complementarity determining region 3 (HCDR3) comprising the amino acid sequence of SEQ ID NO:3; and
(ii) the light chain variable region comprises:
a light chain complementarity determining region 1 (LCDR1) comprising the amino acid sequence of SEQ ID NO:4; a light chain complementarity determining region 2 (LCDR2) comprising the amino acid sequence of SEQ ID NO:5; and a light chain complementarity determining region 3 (LCDR3) comprising the amino acid sequence of SEQ ID NO:6.